er logo points to home page Home page Search Glossary Search Links Database Sitemap Contact Expert Reviews in Molecular Medicine
          Register interest

Expert Reviews in Molecular Medicine: http://www.expertreviews.org/
DOI: 10.1017/S1462399408000689; 9 June 2008
Imran Ahmad, Owen J. Sansom and Hing Y. Leung (2008) Advances in mouse models of prostate cancer. Expert Rev. Mol. Med. Vol. 10, e16, DOI: 10.1017/S1462399408000689

Advances in mouse models of prostate cancer

Imran Ahmad a1 a2 c1, Owen J. Sansom a1 and Hing Y. Leung a1 a2

a1 The Beatson Institute for Cancer Research, Glasgow, UK.

a2 Glasgow Citywide Urology, Greater Glasgow Health Board, Glasgow, UK.

c1 Corresponding author: Imran Ahmad, The Beatson Institute for Cancer Research, Switchback Road, Bearsden, Glasgow, G61 1BD, UK. Tel: +44 141 330 3973; Fax: +44 141 942 6521; E-mail: imranahmad@doctors.net.uk

Advances in science and technology have allowed us to manipulate the mouse genome and analyse the effect of specific genetic alterations on the development of prostate cancer in vivo. We can now analyse the molecular basis of initiation, invasion and progression to metastatic disease. The current mouse models utilise knockout, knock-in or conditional regulation of expression using Cre–loxP technology. Genes that have been targeted include homeobox genes, tumour suppressors and oncogenes, growth factors (and their receptors), steroid hormones and cell-cycle regulators, as well as pro- and anti-apoptotic proteins. Bigenic models indicate that that two ‘hits’ are required for progression from intra-epithelial neoplasia (PIN) to invasion carcinoma, and two to five hits are needed for metastasis. Here, we discuss the numerous models that mimic various aspects of the disease process, such as PIN, locally invasive adenocarcinoma and metastatic disease. Currently the PB-Cre4 × PTENloxP/loxP mouse is the only model that spans the entire continuum from initiation to local invasion and metastasis. Such mouse models increase our understanding of the disease process and provide targets for novel therapeutic approaches. Hopefully, the transgenic models will become inducible and ultimately allow both temporal and spatial gene inactivation. Compound mutational models will also develop further, with double and triple knock-in or knockout systems adding to our knowledge of the interaction between different signalling cascades.

Full text online (purchase or subscribe through Cambridge Journals Online)

| home | search | glossary | links | sitemap | contact |

Expert Reviews in Molecular Medicine © Cambridge University Press ISSN 1462-3994 (Disclaimer and copyright)
Editorial Office: Centre for Applied Research in Educational Technologies (CARET), 1st Floor, 16 Mill Lane, Cambridge, CB2 1SB, UK. Tel: +44 (0)1223 765 375; Fax: +44(0)1223 765 505; E-mail: ermm@caret.cam.ac.uk